摘要
免疫性血小板减少性紫癜(ITP)是最常见的自身免疫性疾病,是由抗体介导的血小板和巨核细胞-血小板生成受损产生的。ITP是一种排除性诊断。最近ITP的病理生理机制和治疗方法已开始出现。虽然类固醇和静脉注射免疫球蛋白(IVIg)仍然是主要的治疗策略,一组患者最终产生了耐药性,尤其是近十年已经有一些生物治疗方案,如利妥昔单抗。在这篇综述中,我们总结了ITP患者的治疗方案,主要集中在时间和生物制剂的潜在影响。
关键词: 自身免疫性疾病,生物治疗,免疫性血小板减少性紫癜,利妥昔单抗。
Current Medicinal Chemistry
Title:Immune Thrombocytopenic Purpura: New Biological Therapy of an Old Disease
Volume: 22 Issue: 16
Author(s): Melda Comert Ozkan, Fahri Sahin and Guray Saydam
Affiliation:
关键词: 自身免疫性疾病,生物治疗,免疫性血小板减少性紫癜,利妥昔单抗。
摘要: Immune Thrombocytopenic Purpura (ITP) is the most common autoimmune disorder that is caused by antibody- mediated destruction of thrombocytes and impaired megakaryocyte platelet production. ITP remains a diagnosis of exclusion. Recent pathophysiologic mechanisms and therapeutical approaches of ITP have emerged. Although steroids and intravenous immunglobulins (IVIg) have still been the main therapeutic strategies, a group of patients develop resistance to those eventually and there have been some biological treatment options such as rituximab especially in the last decade. In this review article, we have summarized the therapeutic options for patients with ITP and mainly focused on the timing and potential effects of biological agents.
Export Options
About this article
Cite this article as:
Melda Comert Ozkan, Fahri Sahin and Guray Saydam , Immune Thrombocytopenic Purpura: New Biological Therapy of an Old Disease, Current Medicinal Chemistry 2015; 22 (16) . https://dx.doi.org/10.2174/0929867322666150319102830
DOI https://dx.doi.org/10.2174/0929867322666150319102830 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Adalimumab
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Monocyte Adhesion in Atherosclerosis: A Biomechanical Approach
Vascular Disease Prevention (Discontinued) Mixed Connective Tissue Disease (MCTD) – A Coming of Age
Current Rheumatology Reviews Therapeutic Targeting of B Lymphocyte Stimulator (BLyS) in the Rheumatic Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Editorial (Thematic Issue: The Thoracic Space: An Amazing Pandora’s Box!)
Current Respiratory Medicine Reviews PCSK9 and LDLR The Yin-Yang in the Cellular Uptake of Cholesterol
Current Hypertension Reviews IgG4 Related Syndrome: Another Multiorgan Disease in the Interest Field of Internal Medicine
Current Pharmaceutical Design Mouse Models of Autoimmune Uveitis
Current Pharmaceutical Design Pharmacological Interactions on Blood Pressure Control in Arterial Hypertension, An Issue not to be Overlooked
Cardiovascular & Hematological Disorders-Drug Targets Covid-19 in Man: A Very Dangerous Affair
Endocrine, Metabolic & Immune Disorders - Drug Targets Tyrosine Kinases and Inflammatory Signalling
Current Molecular Medicine The Immunosuppressive Agent FK506 Prevents Subperineurial Degeneration and Demyelination on Ultrastructural and Functional Analysis
Current Neurovascular Research Clinical Significance of Cytokines and Chemokines in Neuropsychiatric Systemic Lupus Erythematosus
Current Rheumatology Reviews Treatment of Large Vessel Vasculitis
Current Immunology Reviews (Discontinued) Role of Advanced Glycation End Products in Diabetic Neuropathy
Current Pharmaceutical Design Subject Index To Volume 4
Current HIV Research Repositioning of Drugs in Cardiometabolic Disorders: Importance and Current Scenario
Current Topics in Medicinal Chemistry Adverse Cutaneous Reactions of Systemic Antihistamines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents